1. Challenges in chimeric antigen receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma.
- Author
-
Pizzano, Umberto, Facchin, G., Battista, M., Petruzzellis, G., Renzo, G. Di, Fanin, R., and Patriarca, F.
- Subjects
- *
OLDER patients , *LYMPHOMAS , *MANTLE cell lymphoma - Abstract
This letter discusses the challenges in administering a chimeric antigen receptor-T (CAR-T) cell product to an elderly patient with mantle-cell lymphoma. The patient, a 77-year-old woman, had previously undergone chemotherapy and stem-cell transplantation but relapsed and was eligible for CAR-T therapy. However, due to various complications including a femur fracture and a SARS-CoV2 infection, the administration of the CAR-T product had to be postponed. The patient experienced toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR-T infusion, which required treatment with medications such as Tocilizumab and steroids. Despite initial improvement, the patient's condition worsened, and she eventually died. The case highlights the risks and potential complications associated with CAR-T therapy in elderly patients, particularly those with a high tumor burden. The authors suggest that monitoring peripheral CAR-T cells, cytokine levels, and biomarkers such as neurofilament light-chain (NfL) could be helpful in managing toxicities. They also emphasize the need for a better understanding of the pathophysiology of these toxicities and the development of new treatment options for frail patients. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF